Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4- tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35991-36002

  Chen, Chun Han ^a   Lee, Chia Hwa ^b   Liou, Jing Ping ^a   Teng, Che Ming ^b   Pan, Shiow Lin ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Akt; Apoptosis; CRC; EMT; HDAC

Indexed keywords

ACRYLAMIDE DERIVATIVE; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; HISTONE DEACETYLASE 6; MITOGEN ACTIVATED PROTEIN KINASE; N HYDROXY 3 [1 (4 METHOXYPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; VORINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL MOTILITY; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIUM CELL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MESENCHYME CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; ANIMAL; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACRYLAMIDES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HT29 CELLS; HUMANS; MICE; MICE, NUDE; QUINOLONES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946842371     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5475     Document Type: Article

References (32)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5:769-784.
2. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics: official journal of the DNA Methylation Society. 2008; 3:28-37.
3. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011; 71:3635-3648.
4. Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010; 70:3647-3656.
5. Busser B, Sancey L, Josserand V, Niang C, Khochbin S, Favrot MC, Coll JL, Hurbin A. Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation. Mol Ther. 2010; 18:536-543.
6. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011; 7:263-283.
7. Bates RC, Pursell BM, Mercurio AM. Epithelialmesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. Cells Tissues Organs. 2007; 185:29-39.
8. Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs. 2011; 193:23-40.
9. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol. 2011; 27:347-376.
10. Zlobec I. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010; 1:651-661.
11. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature reviews Cancer. 2013; 13:97-110.
12. Liu YM, Lee HY, Chen CH, Lee CH, Wang LT, Pan SL, Lai MJ, Yeh TK, Liou JP. 1-Arylsulfonyl-5-(Nhydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. European journal of medicinal chemistry. 2015; 89:320-330.
13. Cory S. The Bcl family: regulators of the cellular lifeor-death switch. Nature reviews Cancer. 2002; 2:647-656.
14. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature reviews Cancer. 2007; 7:295-308.
15. Yu H. The STATs of cancer-new molecular targets come of age. Nature reviews Cancer. 2004; 4:97-105.
16. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature reviews Cancer. 2009; 9:550-562.
17. Bates RC. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer biology & therapy. 2005; 4:365-370.
18. Suman S, Kurisetty V, Das TP, Vadodkar A, Ramos G, Lakshmanaswamy R, Damodaran C. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells. Molecular carcinogenesis. 2014; 53:E151-160.
19. Larue L. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24:7443-7454.
20. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:104-117.
21. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:1669-1677.
22. Falkenberg KJ. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13:673-691.
23. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res. 2004; 64:1122-1129.
24. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p2 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Molecular cancer therapeutics. 2002; 1:937-941.
25. Glotzer M. The molecular requirements for cytokinesis. Science. 2005; 307:1735-1739.
26. Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PloS one. 2010; 5:e12417.
27. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL, Hsiao PW. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:840-850.
28. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surgical oncology. 2012; 21:316-323.
29. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. The Journal of biological chemistry. 2005; 280:38879-38887.
30. Chen J, Ghazawi FM, Bakkar W, Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Molecular cancer. 2006; 5:71.
31. Chen MC, Chen CH, Liu YN, Wang HP, Pan SL, Teng CM. TW01001, a novel piperazinedione compound, induces mitotic arrest and autophagy in non-small cell lung cancer A549 cells. Cancer Lett. 2013; 336:370-378.
32. Huang HL, Peng CY, Lai MJ, Chen CH, Lee HY, Wang JC, Liou JP, Pan SL, Teng CM. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget. 2015; 6:4976-4991.